Summary: Group Key Figures Q1-2025

Number of Shares 31.03.2025 - 3,991,052 (166,626,687)

Result per share = Result for the period / weighted average number of shares

Equity ratio = Equity / Total assets

Gross Revenue

Gross Revenue refers to the total revenue generated prior to any deductions for price reductions, rebates, or returned goods from wholesalers due to product expiry.

CEO, Jeppe Krog Rasmussen, comments:

Positioning for Sustainable Growth Amid Market Pressures

"Historically, the first quarter has consistently been one of the more challenging periods for our business, and this year has proven to be no exception. We continue to feel the effects of heightened market competition, which has necessitated specific pricing adjustments in response to regulatory-driven dynamics, such as the 14-day dispensing rule. Furthermore, we have experienced a higher-than-usual rate of product returns.

We have proactively adjusted our procurement strategy to reflect these dynamics and accelerated internal initiatives to reduce uncertainty in our operating environment. These efforts are designed to safeguard our margins, strengthen operational efficiency, and better position the Company for sustainable, long-term growth."

Advancing Regulatory Approvals and Expanding the Prescription Portfolio

"We are pleased to report meaningful progress across our prescription (Rx) pipeline. During the quarter, we secured regulatory approval for the updated packaging of our core products: Bedrocan®, Bedica®, and Bediol®.

We are also very happy to inform about the approval for Bedrolite® and Bedrobinol®, which we obtained during May 2025. For more information about this news, please see page 5 and 6 (in the report).

We have also entered into an exclusive distribution agreement with Tetra Pharm Technologies for the Danish market. This partnership gives us rights to their proprietary ZYNDIKATE® delivery system, an advanced formulation platform for lipophilic molecules such as cannabinoids. It enables enhanced protection, superior bioavailability, and controlled release profiles. This is a strategic step in delivering innovative, patient friendly therapies with predictable dosing and improved outcomes.

This agreement aligns strongly with our ambition to lead in cannabinoid based medicines and demonstrates our continued commitment to expanding our technological edge within the sector and represents a significant step towards providing patients with cannabinoid-based treatments that are not only more effective but also offer greater convenience through fixed dosing regimens."

Building the OTC/DTC Platform to Capture New Growth Opportunities

"Progress in our OTC/DTC category remains on track. We are preparing to launch our first products within this space, starting with a range of three botanical extracts. This upcoming launch will establish our presence in the consumer health segment, opening new commercial avenues and further diversifying our revenue streams.

We continue to remain focused on disciplined execution and capital efficient growth strategies. As we move through 2025, we remain committed to delivering on our operational milestones and creating long-term value for our shareholders."

For further information, please contact:

Jeppe Krog Rasmussen, CEO

E-mail: jkr@dancann.com

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm.

For more information, please visit: www.dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

This disclosure contains information that DanCann Pharma A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 23-05-2025.